Must link to the publisher PDF of article on journal website http://www.aacr.org/ subject to Restrictions below, author can archive post-print (ie final draft post-refereeing)
Restrictions:
* 12 months embargo
All documents in ORBi are protected by a user license.
[en] Glioblastomas, the most common primary brain cancers, respond poorly to current treatment modalities and carry a dismal prognosis. In this study, we demonstrated that the transcription factor nuclear factor (NF)-kappaB is constitutively activated in glioblastoma surgical samples, primary cultures, and cell lines and promotes their growth and survival. Sulfasalazine, an anti-inflammatory drug that specifically inhibits the activation of NF-kappaB, blocked the cell cycle and induced apoptosis in several glioblastoma cell lines and primary cultures, as did gene therapy with a vector encoding a super-repressor of NF-kappaB. In vivo, sulfasalazine also significantly inhibited the growth of experimental human glioblastomas in nude mice brains. Given the documented safety of sulfasalazine in humans, these results may lead the way to a new class of glioma treatment.
Disciplines :
Neurology
Author, co-author :
Robe, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Neurochirurgie
Bentires-Alj, Mohamed; Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics
Bonif, Marianne; Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics
Rogister, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Deprez, Manuel ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Haddada, Heddi; Institut Gustave-Roussy, Villejuif, France > Unite´ INSERM 487
Khac, Minh-Tuan Nguyen; Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics
Jolois, Olivier ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine
Erkmen, Kadir; Children’s Hospital, Harvard Medical School, Boston > Department of Neurosurgery
Merville, Marie-Paule ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Black, Peter M; Children’s Hospital, Harvard Medical School, Boston > Department of Neurosurgery
Bours, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Language :
English
Title :
In vitro and in vivo activity of the nuclear factor-kappa B inhibitor sulfasalazine in human glioblastomas.
Publication date :
2004
Journal title :
Clinical Cancer Research
ISSN :
1078-0432
eISSN :
1557-3265
Publisher :
American Association for Cancer Research, Inc. (AACR), Birmingham, United States - Alabama
Doran S, Thorell WE. Brain tumors, population-based epidemiology, environmental risk factors and genetic and hereditary syndromes. In: Win HR, editor. Youmans neurological surgery. Philadelphia: WB Saunders; 2004. p 807-15.
Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (Phila) 1993;71:2585-97.
Gilbert MR, Friedman HS, Kuttesch JF, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 2002;4:261-7.
Murphy C, Pickles T, Knowling M, Thiesse B. Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma. J Neurooncol 2002;57:215-20.
Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-66.
Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999;18:6842-4.
Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-16.
Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340-7.
Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Investig 1997;100:2952-60.
Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20:4188-97.
Bian X, Opipari AW Jr, Ratanaproeksa AB, et al. Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J Biol Chem 2002;277:42144-50.
Nagai S, Washiyama K, Kurimoto M, et al. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 2002;96:909-17.
Gill JS, Zhu X, Moore MJ, et al. Effects of NFkappaB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 2002;23:2773-81.
Leprince P, Rigo JM, Lefebvre PP, et al. In vitro kinetics of a newborn rat astroglia-derived neuronotoxic activity. Neurosci Lett 1989;102:268-72.
Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (Wash DC) 1996;274:782-4.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
Van de Stolpe A, Caldenhoven E, Stade BG, et al. 12-O- Tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994;269:6185-92.
Caldenhoven E, Coffer P, Yuan J, et al. Stimulation of the human intercellular adhesion molecule-1 promoter by interleukin-6 and interferon-gamma involves binding of distinct factors to a palindromic response element. J Biol Chem 1994;269:21146-54.
Caldenhoven E, Liden J, Wissink S, et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the anti-inflammatory action of glucocorticoids. Mol Endocrinol 1995; 9:401-12.
Malgrange B, Rigo JM, Coucke P, et al. Beta-carbolines induce apoptotic death of cerebellar granule neurones in culture. Neuroreport 1996;7:3041-5.
Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
Ansari SA, Safak M, Del Valle L, et al. Cell cycle regulation of NF-kappa b-binding activity in cells from human glioblastomas. Exp Cell Res 2001;265:221-33.
Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 2000;60:1085-9.
Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 2003;61:187-96.
Arlt A, Vorndamm J, Muerkoster S, et al. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002; 62:910-6.
Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002;62:7335-42.
Rayet B, Gelinas C. Aberrant rel/NFkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
Fu DX, Kuo YL, Liu BY, Jeang KT, Giam CZ. Human T-lymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 2003;278:1487-93.
Liu L, Eby MT, Rathore N, et al. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002;277: 13745-51.
Garaventa A, Boni L, Lo Piccolo MS, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 2002;13:956-64.
Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50:137-56.
